Researchers have developed a new, interpretable artificial intelligence (AI) model to predict 5-year breast cancer risk from mammograms, according to a new study published today in Radiology

Image courtesy of Radiology


April 1, 2024 — Researchers have developed a new, interpretable artificial intelligence (AI) model to predict 5-year breast cancer risk from mammograms, according to a new study published today in Radiology, a journal of the Radiological Society of North America (RSNA).

One in 8 women, or approximately 13% of the female population in the U.S., will develop invasive breast cancer in their lifetime and 1 in 39 women (3%) will die from the disease, according to the American Cancer Society. Breast cancer screening with mammography, for many women, is the best way to find breast cancer early when treatment is most effective. Having regularly scheduled mammograms can significantly lower the risk of dying from breast cancer. However, it remains unclear how to precisely predict which women will develop breast cancer through screening alone.

Mirai, a state-of-the-art, deep learning-based algorithm, has demonstrated proficiency as a tool to help predict breast cancer but, because little is known about its reasoning process, the algorithm has the potential for overreliance by radiologists and incorrect diagnoses.

“Mirai is a black box—a very large and complex neural network, similar in construction to ChatGPT—and no one knew how it made its decisions,” said the study’s lead author, Jon Donnelly, B.S., a Ph.D. student in the Department of Computer Science at Duke University in Durham, North Carolina. “We developed an interpretable AI method that allows us to predict breast cancer from mammograms 1 to 5 years in advance. AsymMirai is much simpler and much easier to understand than Mirai.”

About the Mirai Study

For the study, Donnelly and colleagues in the Department of Computer Science and Department of Radiology compared their newly developed mammography-based deep learning model called AsymMirai to Mirai’s 1- to 5-year breast cancer risk predictions. AsymMirai was built on the “front end” deep learning portion of Mirai, while replacing the rest of that complicated method with an interpretable module: local bilateral dissimilarity, which looks at tissue differences between the left and right breasts.

“Previously, differences between the left and right breast tissue were used only to help detect cancer, not to predict it in advance,” Donnelly said. “We discovered that Mirai uses comparisons between the left and right sides, which is how we were able to design a substantially simpler network that also performs comparisons between the sides.”

For the study, the researchers compared 210,067 mammograms from 81,824 patients in the EMory BrEast imaging Dataset (EMBED) from January 2013 to December 2020 using both Mirai and AsymMirai models. The researchers found that their simplified deep learning model performed almost as well as the state-of-the-art Mirai for 1- to 5-year breast cancer risk prediction.

The results also supported the clinical importance of breast asymmetry and, as a result, highlights the potential of bilateral dissimilarity as a future imaging marker for breast cancer risk.

Since the reasoning behind AsymMirai’s predictions is easy to understand, it could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction, Donnelly said.

“We can, with surprisingly high accuracy, predict whether a woman will develop cancer in the next 1 to 5 years based solely on localized differences between her left and right breast tissue,” he said. “This could have public impact because it could, in the not-too-distant future, affect how often women receive mammograms.”

For more information: www.rsna.org


Related Content

News | Bone Densitometry Systems

June 19, 2025 — Naitive Technologies has published results demonstrating the diagnostic performance of its AI-powered ...

Time June 18, 2025
arrow
News | Lung Imaging

June 18, 2025 — Exo recently announced that now included on its Exo Iris is the first ever FDA 510(k) cleared AI for ...

Time June 18, 2025
arrow
Feature | Women's Health | Christine Murray

In breast cancer detection, speed and accuracy are more than clinical goals – they can significantly increase chances ...

Time June 17, 2025
arrow
News | Digital Pathology

June 11, 2025 — Diagnostic laboratory leaders view digital pathology and artificial intelligence (AI) as pivotal to ...

Time June 12, 2025
arrow
News | Lung Imaging

June 11, 2025 — To prepare healthcare workforces and providers for an AI-driven future, Qure.ai has expanded its Global ...

Time June 11, 2025
arrow
News | Radiology Imaging

June 10, 2025 — CIVIE has announced the official launch of RadPod, an AI-driven, on-demand radiology platform designed ...

Time June 10, 2025
arrow
News | Ultrasound Imaging

June 4, 2025 — RadNet, Inc., a provider of high-quality, cost-effective diagnostic imaging services and digital health ...

Time June 09, 2025
arrow
News | Mammography

June 9, 2025 — A new independent, peer-reviewed study published in the journal Clinical Breast Cancer reinforces the ...

Time June 09, 2025
arrow
News | Imaging Software Development

June 05, 2025 — Nano-X Imaging Ltd. has announced that its deep-learning medical imaging analytics subsidiary, Nanox AI ...

Time June 05, 2025
arrow
News | Prostate Cancer

June 5, 2025 – Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time June 05, 2025
arrow
Subscribe Now